Previous Close | 745.95 |
Open | 749.16 |
Bid | 0.00 x 1000 |
Ask | 0.00 x 1100 |
Day's Range | 734.52 - 750.01 |
52 Week Range | 370.68 - 800.78 |
Volume | |
Avg. Volume | 3,050,669 |
Market Cap | 699.006B |
Beta (5Y Monthly) | 0.37 |
PE Ratio (TTM) | 126.32 |
EPS (TTM) | 5.82 |
Earnings Date | Apr 30, 2024 |
Forward Dividend & Yield | 5.20 (0.70%) |
Ex-Dividend Date | Feb 14, 2024 |
1y Target Est | 826.94 |
In this article, we discuss the 13 best low volatility stocks to buy according to hedge funds. To skip the detailed analysis of the current market conditions, go directly to the 5 Best Low Volatility Stocks to Buy According to Hedge Funds. The S&P 500 had a remarkable year in 2023 and the first quarter […]
ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.
Indian drugmaker Biocon , looking to grab a piece of the exploding weight-loss drug market as early as possible, is developing its own version of Novo Nordisk's wildly popular Wegovy and is prepared to conduct a clinical trial next year if needed, the CEO told Reuters. Wall Street has forecast the market for this new generation of obesity treatments reaching at least $100 billion by the end of the decade, and Biocon is taking steps to be a part of that windfall. "We're going to develop semaglutide for India even if it requires a clinical trial," Chief Executive Officer Siddharth Mittal said in an interview of the active ingredient in Wegovy and Ozempic.